Adalimumab plus Methotrexate Is Effective for Patients with Early RA

More patients with rheumatoid arthritis responded to this combination than to methotrexate monotherapy.

Debate is ongoing about the relative efficacy of nonbiologic and biologic therapies for treating patients with rheumatoid arthritis (RA). Triple therapy (hydroxychloroquine, sulfasalazine, and methotrexate) is noninferior to etanercept (Enbrel) plus methotrexate after 2 years (NEJM JW Gen Med Oct 23 2012). Researchers now consider whether the biologic agent adalimumab (Humira) plus methotrexate is more effective than methotrexate monotherapy in patients with early RA.

About 1000 patients with early RA were randomized to methotrexate monotherapy or adalimumab plus methotrexate for 26 weeks. At 26 weeks, nonresponders in either group were switched to open-label combination therapy; methotrexate-monotherapy responders continued that blinded reg…

Reviewing Author

Jonathan S. Coblyn, MD

Disclosures

Consultant / Advisory BoardCVS Health

Editorial BoardsUpToDate

Jonathan S. Coblyn, MD

Disclosures

Consultant / Advisory BoardCVS Health

Editorial BoardsUpToDate

Adalimumab plus Methotrexate Is Effective for Patients with Early RA

Topics

Reviewing Author